

BIOCRYST PHARMACEUTICALS INC

Form 8-K

October 26, 2005

---

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: October 26, 2005**

**BioCryst Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-23186**  
(Commission File Number)

**62-1413174**  
(IRS Employer Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**  
(Address of Principal Executive Office)

**(205) 444-4600**  
(Registrant's telephone number, including area code)

---

**Item 2.02. Results of Operations and Financial Condition:**

On October 26, 2005, the Company issued a news release announcing its financial results for the quarter ended September 30, 2005, which also referenced a conference call to discuss these results and provide an update on the status of the Company's programs. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 9.01 of Form 8-K.

**Item 9.01. Financial Statements and Exhibits:**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated October 26, 2005 entitled BioCryst Reports Third Quarter 2005 Financial Results

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 26, 2005

BioCryst Pharmaceuticals, Inc.

By:                                 /s/ Michael A. Darwin

Michael A. Darwin  
Chief Financial Officer and Chief  
Accounting Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated October 26, 2005 entitled BioCryst Reports Third Quarter 2005 Financial Results